FDA approves new drug for relapsed/refractory multiple myelomaMarch 2, 2020Multiple MyelomaFDA Actions
FDA addresses cell-based regenerative medicine in comprehensive new policyNovember 16, 2017Business of MedicineCellular TherapyFDA Actions
